Rational drug combinations

DerivedModeled

5-drug combinations chosen by greedy max-coverage in pathway space. The chosen drugs have the LOWEST pairwise cosine (most orthogonal mechanisms) and together cover the largest fraction of cancer pathway perturbation. Try k=3 · k=4 · k=5.

Rank	Drugs	Pathway coverage	Mean pairwise cos
1	Pacritinib + Midostaurin + Defactinib + Ponatinib + Brigatinib	3.1%	0.99
2	Bosutinib + Pacritinib + Midostaurin + Defactinib + Ponatinib	3.1%	0.99
3	Abemaciclib + Pacritinib + Midostaurin + Defactinib + Ponatinib	3.1%	0.98
4	Gilteritinib + Pacritinib + Midostaurin + Defactinib + Brigatinib	3.1%	0.99
5	Nintedanib + Pacritinib + Midostaurin + Defactinib + Ponatinib	3.1%	0.99
6	Repotrectinib + Pacritinib + Midostaurin + Defactinib + Ponatinib	3.1%	0.99
7	Pralsetinib + Pacritinib + Midostaurin + Defactinib + Ponatinib	3.1%	0.99
8	Sunitinib + Pacritinib + Midostaurin + Defactinib + Ponatinib	3.1%	0.99
9	Neratinib + Pacritinib + Midostaurin + Defactinib + Ponatinib	3.1%	0.99
10	Dasatinib + Pacritinib + Midostaurin + Defactinib + Ponatinib	3.1%	0.99
11	Fedratinib + Pacritinib + Midostaurin + Defactinib + Ponatinib	3.1%	0.99
12	Fostamatinib + Pacritinib + Midostaurin + Defactinib + Ponatinib	3.1%	0.99
13	Vemurafenib + Pacritinib + Midostaurin + Defactinib + Ponatinib	3.1%	0.99
14	Ripretinib + Pacritinib + Midostaurin + Defactinib + Ponatinib	3.1%	0.99
15	Canertinib + Pacritinib + Midostaurin + Defactinib + Ponatinib	3.1%	0.99
16	Crizotinib + Pacritinib + Midostaurin + Defactinib + Ponatinib	3.1%	0.99
17	Alectinib + Pacritinib + Midostaurin + Defactinib + Ponatinib	3.1%	0.99
18	Entrectinib + Pacritinib + Midostaurin + Defactinib + Ponatinib	3.1%	0.98
19	Tivozanib + Pacritinib + Midostaurin + Defactinib + Ponatinib	3.1%	0.99
20	Vandetanib + Pacritinib + Midostaurin + Defactinib + Ponatinib	3.1%	0.99
21	Selpercatinib + Pacritinib + Midostaurin + Defactinib + Ponatinib	3.1%	0.99
22	Ibrutinib + Pacritinib + Midostaurin + Defactinib + Ponatinib	3.1%	0.98
23	Dacomitinib + Pacritinib + Midostaurin + Defactinib + Ponatinib	3.1%	0.99
24	Dabrafenib + Pacritinib + Midostaurin + Defactinib + Ponatinib	3.1%	0.99
25	Erdafitinib + Pacritinib + Midostaurin + Defactinib + Ponatinib	3.1%	0.99
26	Pazopanib + Pacritinib + Midostaurin + Defactinib + Ponatinib	3.1%	0.99

Next steps

Cross-reference with the existing combination recommender (which scores by target overlap, not pathway coverage) to see which combos appear in both lists — those are the highest-confidence picks.